Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fisogatinib - CStone Pharmaceuticals

Next Previous
Drug Profile

Fisogatinib - CStone Pharmaceuticals

Alternative Names: BLU-554; CS 3008

Latest Information Update: 24 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; CStone Pharmaceuticals
  • Class Acrylamides; Amines; Antineoplastics; Chlorobenzenes; Pyrans; Quinazolines; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer
  • Discontinued Cholangiocarcinoma

Most Recent Events

  • 28 Feb 2024 Blueprint Medicines Corporation completes a phase I trial in Liver cancer (Inoperable/Unresectable) the US, China, France, Germany, Hong Kong, Italy, South Korea, Singapore, Spain, Switzerland, Taiwan, the UK (PO) (NCT02508467)
  • 01 Dec 2022 Pharmacodynamics data from a phase preclinical trial in Hepatocellular carcinoma presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
  • 31 Jan 2022 Blueprint Medicines has patents pending for fisogatinib and and other FGFR4 inhibitors in USA and other countries before January 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top